Virtual ACC 2020 | More Evidence in Support of the Demanding 2017 Hypertension Guidelines

It’s been a while since the demanding and tough 2017 document written jointly between ACC and AHA where, with much controversy, cutoff hypertension values were taken to extreme limits. In fact, more flexible ESC guidelines came out a few months later.

Despite this document, hypertension-related cardiovascular death kept increasing in the US across all age subgroups and regions. 

Results from the present analysis are along the line of prior observational studies. The downward trend in cardiovascular mortality has been slowing down while death for cardiac failure has begun to climb. 

Data to be presented by Dr. Nambiar at the frustrated ACC 2020, to be published simultaneously in JACC, show death for hypertension adjusted by age every 100.000 persons has risen from 18.3 in 2007 to 23 in 2017 (p<0.001 for this trend).


Read also: Virtual ACC 2020 | Myocardial Ischemia Induced by Sudden Mental Stress.


During this same period, cardiovascular death related to hypertension increased 72% in rural US vs 20% in cities (p<0.001 for this trend).

Mortality has increased across all age groups, with the highest impact in people ranging from 65 to 74, for both sexes, but mostly for men.


Read also: Virtual ACC 2020 | “Dangerous” Plaques by CT Effectively Predict Infarction.


The reasons behind this increase are multiple, but clearly diabetes and hypertension epidemics weigh on.

Adjusting to the new cutoff values set in 2017 seems critical.

Original title: Decade long temporal trends in U.S. hypertension related cardiovascular mortality.

Reference: Nambiar L et al. J Am Coll Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...